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Abstract
Background: Human T-cell leukemia virus type I (HTLV-I) has efficiently adapted to its host and establishes a
persistent infection characterized by low levels of viral gene expression and slow proliferation of HTLV-I infected
cells over decades. We have previously found that HTLV-I p30 is a negative regulator of virus expression.
Results: In this study we show that p30 targets multiple cell cycle checkpoints resulting in a delayed entry into S
phase. We found that p30 binds to cyclin E and CDK2 and prevents the formation of active cyclin E-CDK2
complexes. In turn, this decreases the phosphorylation levels of Rb and prevents the release of E2F and its
transcriptional activation of genes required for G1/S transition. Our studies also show that HTLV-II p28 does not
bind cyclin E and does not affect cell cycle progression.
Conclusions: In contrast to HTLV-I, the HTLV-II-related retrovirus is not oncogenic in humans. Here we report that
the HTLV-I p30 delays cell cycle progression while its homologue, HTLV-II p28, does not, providing evidence for
important differences between these two related retrovirus proteins.
Background
Cell cycle progression from G1 to S phase is regulated
by the sequential activationo ft w ok i n a s e - c o m p l e x e s ,
CDK4/6-cyclin D and Cyclin E-CDK2 [1], to ease the
inhibition of E2F-mediated transcription. In G1-phase,
hypo-phosphorylated Rb binds to and sequesters the
E2F-DP1 transcription factors in a repressive complex
containing HDAC, thereby inhibiting the activation of
key downstream transcription events [2]. Following
phosphorylation of Rb by Cyclin D-CDK4/6 and subse-
quently by Cyclin E-CDK2, E2F is released from the
repressor complex Rb-E2F allowing activation of key
genes required for S-phase entry [3].
Unlike the cyclin D-dependent kinases, the activity of
cyclin E-Cdk2 is intermittent and reaches a maximum
at the G1- to S-phase transition [4-6]. Cyclin E expres-
sion and activity is at least in part mitogen-dependent,
and its downstream targets include a subset of the G1
inhibitors that are also targeted by the D-type cyclins,
Rb and p27Kip1. However, the mechanisms by which
cyclin E inactivates these inhibitors differ from those
used by cyclin D-dependent kinases, suggesting that
their actions may be complementary [7,8]. Cyclin
E-Cdk2 phosphorylates Rb on different sites from the
cyclin D-dependent kinases, and may differentially affect
interactions of Rb with E2Fs, histone deacetylases, and
other chromatin-remodeling factors [9]. The functions
of cyclin E-Cdk2 are not strictly limited to G1. Cyclin
E-Cdk2 phosphorylates a second set of substrates that
are involved in cell duplication; these events affect his-
tone gene expression, centrosome duplication, replica-
tion origin licensing, and, possibly, origin firing [10].
Cyclin E is one of the E2F-responsive genes. Once the
E2F transcriptional program is initiated and sufficient
levels of cyclin E-dependent Cdk2 activity is attained,
cells no longer rely on the cyclin D-dependent kinases
nor on persistent mitogenic signals and are committed
to complete the cell cycle [11].
Human T-cell leukemia virus type I (HTLV-I) was ori-
ginally isolated from a patient with cutaneous T-cell
lymphoma [12]. HTLV-I is the causative agent of adult
T-cell leukemia (ATL) [13] and tropical spastic parapar-
esis/HTLV-associated myelopathy (TSP/HAM) [14,15].
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excessive proliferation of HTLV-I infected T cells [16].
Numerous studies have reported the ability of Tax to
target cell cycle checkpoints [17-23]. However, recent
studies also suggest that infection with HTLV-I or Tax
expression itself may not be sufficient for a sustained
active cellular proliferation and that accumulation of
genetic defects may be required to bypass cell cycle
checkpoints [24-26]. This would in fact explain the abil-
ity of HTLV-I transformed cells to proliferate in vivo in
the absence of most viral gene expression. Additional
studies also showed that several virus-encoded genes,
p13, p30, p12 and HBZ, adversely affect cell cycle pro-
gression [27-34].
We previously demonstrated that p30 is a post-
transcriptional repressor of HTLV-I replication [35].
Additional observations suggested that p30 is a multi-
functional protein that selectively regulates cellular
and viral gene expression and delays infected cells in
their progression to the G2 phase of the cell cycle
[28,29,36-40]. In the present study, we show that
HTLV-1 p30 delays the cell cycle before the entry into S
phase. We also show that the effect of p30 is due to its
interaction with the cyclin E key-trigger of the G1/S
transition, which in turn reduces the function of the
Cyclin E-CDK2 complex and all the downstream events.
Methods
Plasmids and lentiviral particles
Lentiviral particles expressing p30-myc or GFP were
prepared by transfection of 293FT cells with HR-CMV-
p30myc or GFP with pDLN and VSV-G, respectively, as
previously reported [35]. The genes encoding for
HTLV-I p30 and its homologue, HTLV-II p28, proteins
were amplified by PCR and cloned in frame with an HA
tag of pMH vectors into the HindIII and EcoRI sites.
The same sites were used to clone both genes in frame
with GFP in pEGFPC1 (clonetech). Cyclin E-myc and
CDK2-HA expression vectors were a gift from James M.
Roberts [41].
Cell Culture and transfection
Hela cells and 293FT were obtained from the ATCC
(American Type Culture Collection). They were main-
tained in Dubelcco modified Eagle medium, DMEM,
complemented with 10% of fetal bovine serum (Gibco)
and 1% penicillin-streptomycin. Jurkat T cells were cul-
tured in RPMI complemented with 10% of fetal bovine
serum (Gibco) and 1% penicillin-streptomycin. Cells
were maintained at 37°C in a humid incubator with 5%
CO2 concentration. Polyfect transfection reagent (Qia-
gen) and Calcium phosphate complexes (Invitrogen)
were used to transfect HeLa and 293FT cells, respec-
tively. The luciferase reporter (pGL3) whose expression
is driven by six E2F responsive elements (6xE2F-Luc)
[42] was used for the transcriptional activity of E2F pro-
teins. 293T cells were transfected with 6xE2F-Luc along
with increased amounts of HTLV-1 p30 or HTLV-2 p28
expression vectors. After 24 h of transfection, the cells
were starved overnight with media containing 0.5% FBS
and then were serum activated (15% FBS) for 5 h fol-
lowed by luciferase activity assays of the cell extracts as
previously reported [42].
Cell cycle and Flow Cytometry analyses
For cell cycle synchronization and release, 10 h after
transfection (GFP vectors), cells were treated overnight
with Hydroxyurea (2 mM) to arrest cells in the G1
phase of the cell cycle. They were next washed and
released from block for the time indicated in the figure
legends. For the accurate counting of cells going
through the cell cycle, in some experiments cells were
treated with Nocodazole (40 ng/ml) after release from
Hydroxyurea to block them in G2/M. For the cell cycle
distribution analysis, cells were resuspended in media
containing the Dye Cycle Violet (Excitation at 405 nm
and Emission at 450 nm) (Invitrogen) and incubated for
30 min at 37°C before being analyzed by an LSRII flow
cytometer using FACS DIVA 6.1 software.
Immunocytofluorescence staining and microscopy
GFP or p30-myc expressing viruses have been titered by
immuno-fluorescence to reach 100% of cells transduced.
For immunostaining, Hela cells seeded on coverslips
were transduced for 48 Hours with the viral particles
expressing p30-myc. They were then fixed in 3.7% Par-
aformaldehyde (PFA) for 15 min at RT, washed with
PBS for 5 min followed by permeabilization with 0.5%
Triton X-100 on ice for 5 min. They were next blocked
for 1 h in PBS with 0.5% gelatin and 0.25% bovine
serum albumin at room temperature. Cells were incu-
bated overnight with anti-myc primary antibody (9E10,
Roche), washed 3 times with PBS plus gelatin 0.2% and
then incubated with anti Mouse Alexa-596 conjugated
secondary antibody (Invitrogen). They were next washed
and mounted by using DABCO mounting medium
(2.5% DABCO from Sigma, 200 mM Tris-HCl pH8.6
and 90% glycerol). Fluorescent images were captured by
using a Nikon Ti-S epifluorescence microscope
equipped with a device camera and the NIS elements
software (Nikon). The images were collected by using
the objectives 20× and 100×.
RNA extraction and Real time RT-PCR
The expression of E2F, cyclinE and p21 was quantified
by real time PCR using the Sybr Green method (Applied
Biosystems). Briefly, the total mRNA of cells transfected
or not transfected with the p30 expression vector was
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s c r i b e du s i n gt h eH i g hc a p a c i t yR N At oc D N Ak i t
(Applied Bioscience) as recommended by the manufac-
turer. Real time PCR (40 cycles) was performed in a total
of 25 ul containing RT master mix, water, primers at 0.5
uM each and cDNA as recommended by the manufac-
turer using Applied Bioscience Step One plus real time
PCR Software. The GAPDH gene was used as an internal
amplification control. GAPDH primers: Forward 5’-
gaaggtgaaggtcggagtc-3’ and Reverse 5’-gaagatggtgatgg-
gatttc-3’. Real time primers: cyclinE forward: tcagggtat-
cagtggtgcga, cyclinE reverse: caaatccaagctgtctctgtg, p21
forward: tgcgttcacaggtgtttctg, p21 reverse: gccattagcgcat-
cacagt, E2F forward: accctgacctgctgctctt and E2F reverse:
tctcggccaggtactgatg. The results are determined by the
Relative Standard Curve and comparative CT Experi-
ments. The fold = 2
-DDCT.
Immunoprecipitation, western blots and antibodies
Cell extracts were prepared using NP-40 lysis buffer (1%
NP-40, 50 mM Tris-HcL (pH7.5)), 150 mM NaCl, and a
set of proteases (inhibitors). The immunoprecipitation
was performed overnight and the proteins were sepa-
rated by SDS page, transferred to PVDF membrane and
western blotted using the standard protocol of WB:
Blocking with TBS/Milk 5%, primary antibody overnight
incubation and secondary antibody 2 h incubation (in
TBS Milk 2%), washed 3 times in TBST 0.05% and sig-
nals were revealed with super signal chemiluminescent
substract (Thermo Scientific). Primary antibodies used
in this study: Rabbit polyclonal anti phospho(Thr821/
826)-Rb (Santa Cruz), Goat polyclonal anti Actin sc-
1615 (Santa Cruz), Rabbit polyclonal anti cyclinE (Santa
Cruz C-19 clone), Mouse monoclonal anti-myc tag
(9E10) and Mouse monoclonal anti-HA (3F10), Mouse
monoclonal anti Flag (Roche), goat polyclonal anti Rb
sc-50-G (Santa Cruz), Rabbit polyclonal anti E2F-1 sc-
193 (Santa Cruz), Mouse monoclonal anti PCNA (pc10,
ZYMED) and Rabbit polyclonal anti p21waf sc-397
(Santa Cruz).
Results
Using genome-wide microarray analyses, we and others
have previously shown that HTLV-I regulatory protein
p30 modulates a number of genes involved in the cell
cycle. In addition, p30 has been shown to promote the
accumulation of cells in the G2-M phase of the cell
cycle to facilitate early viral spread and increase T-cell
survival following infection [29]. Since our previous data
suggested that p30 alters expression of genes involved in
G1/S progression [28], we investigated the possible role
of p30 in early phases of the cell cycle. To facilitate ana-
lyses of p30 expressing cells by FACS, p30 was cloned
into a vector containing an internal ribosome entry site
(IRES) fused to the green fluorescent protein (GFP).
Cells transfected with GFP-p30 or GFP vector were trea-
ted overnight with Hydroxyurea (HU) in order to
synchronize cells in the G1 phase of the cell cycle
(Figure 1A). Approximately, 75% of p30-expressing or
GFP control cells were successfully blocked in G1, and
the percentage of p30-expressing or GFP control cells in
S and G2/M were similar (Figure 1A). Cells were
washed, released from arrest for eight hours before the
cells were collected, stained with DyeCycle violet and
the GFP expressing cells gated by FACS for cell cycle
analyses. Interestingly, while the majority of GFP expres-
sing cells progressed to G2/M phase (green), p30-
expressing cells were significantly delayed and were still
mostly in S phase (red). Since HU did not block 100%
of the cells and to prevent the reentry of cells from
G2/M to G1, we repeated this experiment in the pre-
sence of nocodazole, an inhibitor of the mitotic spindle
formation that promotes arrest of Jurkat cells in G2/M
[43]. In this experiment the initial time point prior to
release is the same as in Figure 1A. The results pre-
sented above suggested that p30-expressing cells were
delayed in G1/S progression and/or during DNA repli-
cation in S phase. To differentiate between these two
possibilities, we analyzed cells four hours after release.
Data indicated that p30-expressing cells were still in
G1/S (80%) while GFP control cells already entered S
phase, about 50% for only 10% of p30-expressing cells
(Figure 1B). These results suggest that p30-expressing
cells are mainly delayed at the G1/S border and their
entry into S phase. Our results also suggest that p30
delays, but does not block cell cycle progression, since
eight hours after release most p30-expressing cells are
in S phase (68%)(Figure 1B). Again, while most GFP
expressing cells are in G2/M (80%) eight hours after
release, only about 20% of p30-expressing cells are in
G2/M (Figure 1B). Collectively, our results demonstrate
that p30 prevents normal cell cycle progression, retains
cells in G1 and favors a cellular resting state. To con-
firm our results in human T cells, the natural target of
HTLV-I, we used lentiviral vectors to tansduce p30 or
GFP into Jurkat. Twenty four hours after infection, cells
were synchronized with HU and released for cell cycle
p r o g r e s s i o na tt i m et=0a n dt=8h o u r s .T h er e s u l t s
presented in Figure 1C further demonstrate that p30
transduced Jurkat cells were significantly delayed
in S-phase entry when compared to GFP transduced
Jurkat cells.
We next wanted to study the effect of p30 on the
expression of endogenous G1/S regulators. Since trans-
fection efficiencies are not sufficient for such studies, we
cloned p30 with a carboxy-terminal myc tag into a lenti-
viral vector. High titer pseudotype virus particles were
prepared by transfection of 293FT cells with HR-CMV-
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also prepared in the same conditions, titered by
immuno-fluorescence and used as control. Expression of
p30 was readily detected by western blot using an anti-
m y ca n t i b o d yf o r t y - e i g h th o urs after infection of HeLa
cells (Figure 2A), and, in our experimental conditions,
nearly 100% of cells were transduced, as shown by
immuno-fluorescence detection of p30 (Figure 2B).
Using the above experimental conditions, we analyzed
the expression of proliferating cell nuclear antigen
(PCNA), a protein involved in replication of the DNA
and required for entry and progression of cells in S
phase. The results showed that p30 expression signifi-
cantly reduced PCNA expression at the protein level
(Figure 2C).
We next tested the expression of several regulators of
the G1/S transition, E2F, cyclin E and histone H2A, by
quantitative real time RT-PCR. Our results showed sig-
nificant down-regulation of E2F and cyclin E mRNA in
t h ep r e s e n c eo fp 3 0( F i g u r e2 D ) .W ed i dn o ts e ea n y
significant change in H2A levels (data not shown).
These data were further confirmed at the protein level
by western blot analyses (Figure 2E). Since E2F is a key
transcriptional regulator of genes involved in S phase
entry [44], decreased expression of E2F in part explains
the reduced expression of PCNA and cyclin E (Figure
2C and 2D). Our studies also revealed an increased
expression of p21waf CDK-inhibitor at both RNA and
protein levels (Figure 2D and 2E). Although many
genes, including E2F itself, are transcriptionally regu-
lated by E2F, our results shown in Figure 2F suggested
that p30 do not directly affect E2F transcriptional activ-
ity. Overall, our results suggest that p30 alters cell cycle
progression by targeting multiple checkpoints involved
in the G1/S transition, thereby preventing S phase entry.
Whereas cyclin D/cyclin dependent kinase (CDK) 4
and 6 control early G1, progression through G1/S is
controlled by the cyclin E-CDK2 complexes. In the
absence of Cyclin E-CDK2 activity, E2F remains bound
to Rb and cannot activate the transcription of genes
involved in S phase entry. Previous studies have shown
that Tax directly alters the ratio of Rb-bound and Rb-
unbound E2F resulting in activation of E2F-dependent
transcription and S-phase entry [45]. Activity of the
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Figure 1 HTLV-1 p30 delays entry of cells into S phase of the cell cycle. Hela cells were transfected with GFP (green) control or GFP-p30
(red) expression vectors synchronized with Hydroxyurea (2 mM) and then released for 0 h or 8 h A). B) The same experiment was performed as
in A) but after release from “HU” block, cells were immediately treated for 4 h or 8 h with Nocodazole (40 ng/ml) to prevent the reentry of cells
from G2/M to G1. The cell cycle was assessed by flow cytometry of GFP positive gated cells. Histograms indicating the percentage of cells in
each phase of the cell cycle shown in A) and B), respectively. C) Jurkat cells infected with lentiviral particles expressing p30 or GFP were
synchronized overnight with HU (2 mM) and then released for 0 h and 8 h. Cells were stained with propidium iodide (PI) and analyzed by Flow
cytometry for the cell cycle distribution using the FACS DIVA 6.1 and FlowJo7.5 Softwares.
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mechanisms, including activation of CDK2 by phosphor-
ylation [46] or alterations in the stoichiometry of cyclin
dependent kinase inhibitors (CDKI) p21
Waf1 and p27
Kip1
bound to cyclin E [47]. To identify which of these
mechanisms may be associated with p30-mediated inhi-
bition of G1/S progression, the active form of CDK2
bound to cyclin E was detected by immuno-precipitation
of cyclin E from protein extracts of cells transfected
with cyclin E-myc and CDK2-HA in the presence or the
absence of p30-Flag. Our results demonstrated that the
amounts of active CDK2 bound to cyclin E is severely
reduced in the presence of p30 (Figure 3A and 3B).
Consistent with these findings we also found that in the
presence of p30, decreased amounts of active Cyclin
E-CDK2 complexes correlated with reduced hyperpho-
sphorylation of Rb p107 (Figure 3C). It is well known
that in the absence of phosphorylated Rb, E2F cannot
be released and cannot activate the transcription of
genes required for S phase entry. We next investigated
whether p30 may interact with either cyclin E or CDK2.
Specific interactions between p30 and cyclin E were
readily demonstrated by co-immunoprecipitation and
western blot assays after transfection of 293T cells
(Figure 3D). Similarly, we found that p30 forms a com-
plex with CDK2 (Figure 3E). Our results suggest that
p30 interacts with cyclin E and CDK2 reducing Cyclin
E-CDK2 complex formation and phosphorylation of Rb.
While HTLV-I is the etiological agent of ATL and
TSP/HAM, infection with HTLV-II is not oncogenic in
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Figure 2 p30 decreases the expression of proteins involved in S phase entry and progression. Hela cells were transduced for 48 h with
GFP (control) or p30-myc expressing lentivirus. A) p30-myc expression was detected by western blot (WB) using anti-myc antibody or B)b y
indirect immunofluorescence (IF) staining. Nearly 100% of cells were transduced as shown with different magnifications. GFP-viral particles
(HRCMV-GFP) were used as a control in the IF staining. C) WB analysis of PCNA protein was performed in the same experimental conditions.
D) Quantification of E2F, cyclin E and p21waf mRNAs by real time PCR. E2F, Cyclin E and p21waf values were normalized to that of GAPDH
which was used as an internal control. E) Extracts of Hela cells transduced with GFP or p30-myc virus were used for WB analyses of the
endogenous E2F, cyclin E and p21 proteins. F) 293T cells were transfected with 6xE2F-Luciferase reporter plasmid either with HTLV-1 p30 or
HTLV-2 p28 expression vectors. Histograms represent the values of three different experiments with their standard deviations. WB analyses
showing equal amounts of p30 and p28 are present in the cell extracts.
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p30 homologue, HTLV-II p28 [48], on cyclin E and the
cell cycle. To compare p30 and p28 biological activities
we cloned both viral genes into the same vector (pMH)
with the same tag (HA). Following transfection of 293T
cells, our results consistently showed that the HTLV-II
p28 protein expressed 25 to 30 fold higher than the p30
protein (Figure 4A). This difference in levels of expres-
sion between p30 and p28 was consistently observed
and was not related to differences in transfection effi-
ciency (Figure 4B). Using normalized protein amounts,
we found that, in contrast to p30, p28 was not able to
bind cyclin E (Figure 4C) following transient expression
in 293T cells, unless p28 was overexpressed at extremely
high levels (data not shown). Finally, cell cycle analyses
revealed that p28 does not stop the progress of cells in
the transition from G1 to S phase as does p30 (Figure
4D and 4E), thereby providing the first evidence of a
functional difference between these two proteins.
Discussion
Because HTLV-I is highly immunogenic and presents a
low variability, reducing expression of viral proteins is
essential to virus maintenance in vivo.I nf a c t ,w h i l e
HTLV-I expression can be detected in TSP/HAM
patients, the virus is mainly silent in ATL patients [49]
and expansion of infected cells occurs through cell divi-
sion rather than de novo infection [50]. We have pre-
viously discovered that the p30 complex with the tax/
rex mRNA prevents its nuclear export, thereby repres-
sing virus expression [35]. This may be advantageous for
the establishment of a latent and persistent infection.
We also showed that p30 decreases Toll-like receptor 4
(TLR4) signaling and inhibits the production of pro-
inflammatory cytokines (macrophage chemoattractant
protein 1(MCP-1), tumor necrosis factor alpha (TNF-a),
and interleukin 8 (IL-8)), while increasing the release of
the anti-inflammatory cytokine IL-10 [38]. These find-
ings may in part explain the inability of dendritic cells
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Figure 3 p30 interacts with Cyclin E and CDK2 and reduces formation of the Cyclin E-CDK2 complex. A and B) p30 disrupts interactions
between Cyclin E and CDK2. 293T cells were tranfected with Cyclin E-myc, p30-flag and CDK2-HA. The interactions between Cyclin E and CDK2
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(E) CDK2 and p30 were investigated after transient transfection in 293T cells and Co-IP/WB.
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Page 6 of 10to activate adaptive immunity in ATL patients and the
limited proliferation of virus-specific cytotoxic T-lym-
phocytes (CTL) reported in ATL patients. Previous stu-
dies have shown that p30 can delay the progression of
cells during G2/M by enhancing Chk-1 phosphorylation
and reducing expression of Polo-like kinase (PLK1) [29].
In the present study, we demonstrate that the HTLV-I
accessory protein p30, but not its HTLV-II homologue
p28, delays entry of cells into S phase and cell cycle pro-
gression. While proliferation of infected cells is required
at times, uncontrolled proliferation of infected cells may
lead to their activation and expression of viral genes.
Therefore, it seems logical that the virus evolved pro-
teins to balance proliferation as well as mechanisms to
p r e v e n ti n f e c t e dc e l l sf r o mr a p i dc e l ld i v i s i o n .O u r
results demonstrate that p30 activates multiple G1/S
checkpoints to reduce proliferation. We did not detect
any significant change in H2A mRNA levels of expres-
sion in p30 expressing cells. We think that this may be
due to the fact that p30 targets factors involved in S
phase entry and regulated by E2F. In contrast H2A acti-
vation is E2F-independent and occurs after cells have
entered S phase. Cyclin-dependent kinase inhibitor
(CDKI) p21waf expression was increased in p30 expres-
sing cells. We do not know the mechanism by which
p30 increases p21waf expression at the moment and
additional studies are needed to investigate whether p30
affects the expression of p21waf by increasing its pro-
moter expression or mRNA stability. Alternatively p30
may affect other cellular factors involved in p21waf
expression such as p53 or Mdm2. We found a signifi-
cant reduction in E2F and Cyclin E expression at both
the transcriptional and protein levels. We do not think
that p30 directly affects E2F promoter, since we did not
see significant effects of p30 on E2F-mediated transcrip-
tional activation of an E2F reporter construct. Instead,
we found that p30 interacts with both Cyclin E and
CDK2 preventing the formation of active Cyclin
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loading control. B) Hela cells were transfected with p30HA or p28HA along with GFP expression vector and GFP expression was monitored to
demonstrated equivalent transfection efficiencies. C) p28 does not interact with Cyclin E. 293T cells were transfected either with Cylin E-myc and
p30-HA or cyclin E-myc and p28-HA. Cell extracts were prepared and the interaction in vivo between Cyclin E and both viral proteins were
assessed by co-immunoprecipitation. D) p28 does not affect the cell cycle progression. Hela cells were transfected either with GFP-p30 or GFP-
p28 expression vectors, synchronized with Hydroxyurea (2 mM) and then released for 0 h, 8 h. The cell cycle distribution was assessed by flow
cytometry of GFP positive gated cells using the Dye cycle Violet. E) Histograms indicating the percentage of cells in each phase of the cell cycle
distribution.
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Page 7 of 10E-CDK2 complexes. Our data may suggest that like
p21waf, p30 may form a ternary complex with these
proteins further studies are needed to clarify the
mechanism. Whether p30 prevents the formation of
Cyclin E-CDK2 complexes by sub-cellular compartmen-
talization to the nucleolus or recruitment of additional
cellular factors is currently under investigation. The
effects of p30 on the cyclin E-CDK2 complex was asso-
ciated with a significant decreased phosphorylation of
Rb and delayed entry into S phase.
In contrast to a previous study [29] using a stable
transfected p30 Jurkat cell line, we did not observe a sig-
nificant delay of p30 expressing cells in progression
through G2/M in our assays. While the systems used
are quite different, it is possible that selection of p30
expressing cells in that study resulted from elimination
of cells with a significant delay in G1/S entry. On the
other hand it is possible that the G2/M accumulation
previously reported for p30 expressing cells is in fact the
result of a delay of these cells in S phase entry. Thus
entry of p30 expressing cells into G2/M occurs later
while control cells have already completed their cycle
and are in G1. In fact, when p30 expressing and control
cells were synchronized in G2/M using nocodazole and
released we did not see any delayed cell cycle progres-
sion from G2/M to G1. However, it is still possible that
nocodazole does not block cells early enough in G2 to
expose p30 effects. Clearly additional experiments are
needed to clarify these issues.
Together our data lead to a model (Figure 5) in which
p30 prevents the release of E2F from Rb, thereby pre-
venting E2F-mediated transcription of genes involved in
the transition of G1 to S as well as its own expression.
Interestingly, these effects of p30 would be predicted to
antagonize those of Tax, which inactivates or overrides
cell cycle checkpoints and stimulates cell proliferation.
Differences between Tax and p30 are, however, not
completely unexpected given the opposite functions of
p30
E2F
Cyclin
E
CDK2
p27 p21
Rb
E2F
Genesinvolvedin
G1/Stransition
E2F,CyclinE,Rb,...
E2F
Cyclin
E CDK2
p27 p21
Genesinvolvedin
G1/Stransition
G1 S G2 M
E2F,CyclinE,Rb,...
G1 S G2 M
Rb
E2F
Figure 5 The progression through G1/S transition in the presence or absence of HTLV-1 p30.H T L V - 1p 3 0d i s r u p t st h ei n t e r a c t i o n
between CDK2 and Cylin E and the capacity of this complex to phosphorylate Rb. E2F becomes sequestered by Rb and is not available to
activate the expression of genes involved in G1/S transition.
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Page 8 of 10these two proteins during the virus life cycle. Interest-
ingly, our data demonstrate that the HTLV-II p28 pro-
tein does not interact with cyclin E and does not
significantly impair cell cycle progression. This is the
first report of a physiological difference between p30
and p28. Because HTLV-I, but not HTLV-II, is asso-
ciated with leukemias, any difference between these
viruses may offer some clues about the determinant of
viral pathogenesis of HTLV-I.
In addition to p30, other HTLV-I-encoded small pro-
teins play a critical role in evasion of infected cells to
immune defenses and survival of tumor cells. p12 has
been shown to down regulate MHC class I from the cell
surface and to increase the release of calcium from the
endoplasmic reticulum to activate NFAT-mediated tran-
scription [30,31,51-54]. Finally, proteolytic processing of
p12 generates a shorter 8-kDa protein that migrates to
the cell surface, interacts with the immunologic synapse
following engagement of the T-cell receptor (TCR), and
down-regulates TCR signaling [55]. p13, a mitochondrial
protein, induces a delay in all phases of the cell cycle
and appears to be mediated by up-regulation of a heat-
sensitive cellular cytostatic factor [27]. These studies
suggest that HTLV-I accessory proteins may play critical
roles in slowing the replication of HTLV-I infected cells
in vivo to prevent their elimination by the host’s
immune cells. A better understanding of how this is
achieved may offer new ways to interfere with viral
latency, expose infected cells to the immune system and
help their eradication.
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E2F: HTLV-I; PCNA: Rb.
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